Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Hulstaert · SciRah

Researcher profile · Semantic Scholar

F. Hulstaert

Share profile

F. Hulstaert — researcher profile on SciRah

h-index: 20
Works: 80
Citations: 1,663

Most-cited papers

Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies.
L. Veldeman, I. Madani, F. Hulstaert, G. De Meerleer +2 more
2008The Lancet Oncology368 citations
Semantic Scholar
Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers.
R. Leroy, N. Benahmed, F. Hulstaert, N. Van Damme +1 more
2016International Journal of Radiation Oncology, Biology, Physics111 citations
Semantic Scholar
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
J. Declercq, Karel F. A. Van Damme, E. de Leeuw, B. Maes +39 more
2021The Lancet Respiratory Medicine108 citations Open access
Semantic Scholar
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer.
R. Saesen, M. van Hemelrijck, J. Bogaerts, C. Booth +14 more
2023European Journal of Cancer92 citations Open access
Semantic Scholar
Transcatheter aortic valve implantation (TAVI): risky and costly
H. van Brabandt, M. Neyt, F. Hulstaert
2012British medical journal79 citations
Semantic Scholar
Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis
M. Neyt, F. Hulstaert, W. Gyselaers
2014BMJ Open74 citations Open access
Semantic Scholar
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
María-Isabel Farfan-Portet, Sophie Gerkens, I. Lepage-Nefkens, Irm Vinck +1 more
2013European Journal of Health Economics68 citations Open access
Semantic Scholar
Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Mattias Neyt, M. Huybrechts, F. Hulstaert, F. Vrijens +1 more
2008Health Policy55 citations
Semantic Scholar
Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost?
Y. Lievens, C. Obyn, Anne-Sophie Mertens, Dries Van Halewyck +1 more
2015Journal of Thoracic Oncology50 citations Open access
Semantic Scholar
PRE-MARKET CLINICAL EVALUATIONS OF INNOVATIVE HIGH-RISK MEDICAL DEVICES IN EUROPE
F. Hulstaert, M. Neyt, I. Vinck, S. Stordeur +9 more
2012International Journal of Technology Assessment in Health Care47 citations Open access
Semantic Scholar
Recommendations for robust and reproducible preclinical research in personalised medicine
V. Fosse, E. Oldoni, Florence M. Bietrix, A. Budillon +29 more
2023BMC Medicine44 citations Open access
Semantic Scholar
Silicone adhesive multilayer foam dressings as adjuvant prophylactic therapy to prevent hospital‐acquired pressure ulcers: a pragmatic noncommercial multicentre randomized open‐label parallel‐group medical device trial
D. Beeckman, A. Fourie, C. Raepsaet, N. Van Damme +20 more
2020British Journal of Dermatology44 citations Open access
Semantic Scholar
Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy?
B. Wieseler, M. Neyt, T. Kaiser, F. Hulstaert +1 more
2023British medical journal38 citations
Semantic Scholar
Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening
Nancy Thiry, C. De Laet, F. Hulstaert, M. Neyt +2 more
2009International Journal of Technology Assessment in Health Care35 citations
Semantic Scholar
Direct-to-consumer genetic testing services
P. Borry, H. Poirel, S. Baatout, B. Blaumeiser +16 more
201232 citations
Semantic Scholar
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
M. Trøseid, J. Arribas, L. Assoumou, A. R. Holten +411 more
2023Critical Care29 citations Open access
Semantic Scholar
Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agency
H. Nevens, J. Harrison, F. Vrijens, L. Verleye +3 more
2019Trials25 citations Open access
Semantic Scholar
Gaps in the evidence underpinning high-risk medical devices in Europe at market entry, and potential solutions
F. Hulstaert, Céline Pouppez, Célia Primus-de Jong, K. Harkin +1 more
2023Orphanet Journal of Rare Diseases21 citations Open access
Semantic Scholar
Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country
G. Molenberghs, M. Buyse, S. Abrams, N. Hens +15 more
2020Contemporary Clinical Trials21 citations Open access
Semantic Scholar
Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
Alain Denis, L. Mergaert, Christel Fostier, I. Cleemput +2 more
2011PharmacoEconomics (Auckland)20 citations
Semantic Scholar
Contingent non‐invasive prenatal testing: an opportunity to improve non‐genetic aspects of fetal aneuploidy screening
W. Gyselaers, F. Hulstaert, M. Neyt
2015Prenatal Diagnosis15 citations
Semantic Scholar
Barriers and opportunities for the uptake of biosimilar medicines in Belgium
I. Lepage-Nefkens, Sophie Gerkens, I. Vinck, J. Pierart +2 more
201315 citations Open access
Semantic Scholar
Publicly funded practice-oriented clinical trials: of importance for healthcare payers.
M. Neyt, T. Christiaens, J. Demotes, T. Walley +1 more
2016Journal of Comparative Effectiveness Research14 citations
Semantic Scholar
The importance of test accuracy in economic evaluations of companion diagnostics.
Lorena San Miguel, F. Hulstaert
2015Journal of Comparative Effectiveness Research13 citations Open access
Semantic Scholar
Valorising and Creating Access to Innovative Medicines in the European Union
L. Annemans, I. Cleemput, F. Hulstaert, S. Simoens
2011Frontiers in Pharmacology13 citations Open access
Semantic Scholar
Towards a better managed off-label use of drugs
Céline Vannieuwenhuysen, Pierre Slegers, Mattias Neyt, F. Hulstaert +3 more
201512 citations Open access
Semantic Scholar
Innovative radiotherapy techniques: a multicentre time-driven activity-based costing study
F. Hulstaert, Anne-Sophie Mertens, C. Obyn, Dries Van Halewyck +2 more
2013KCE Reports12 citations Open access
Semantic Scholar
Pharmaceutical and non-pharmaceutical interventions for Alzheimer’s Disease, a rapid assessment.
F. Hulstaert, Nancy Thiry, Marijke Eyssen, France Vrijens
2009KCE Reports12 citations Open access
Semantic Scholar
Hadron therapy in children – an update of the scientific evidence for 15 paediatric cancers
R. Leroy, N. Benahmed, F. Hulstaert, F. Mambourg +3 more
2015KCE Reports11 citations Open access
Semantic Scholar
The pre-market clinical evaluation of innovative high-risk medical devices
F. Hulstaert, Mattias Neyt, I. Vinck, S. Stordeur +6 more
201111 citations Open access
Semantic Scholar
Market introduction of innovative high risk medical devices: towards a recast of the directive concerning medical devices.
I. Vinck, F. Hulstaert, H. van Brabandt, M. Neyt +1 more
2011European Journal of Health Law11 citations
Semantic Scholar
Expanded carrier screening in a reproductive context. Towards a responsible implementation in the healthcare system
P. Borry, J. Cassiman, F. Hulstaert, I. Liebaers +6 more
201710 citations
Semantic Scholar
Future scenarios about drug development and drug pricing
Philippe Vandenbroeck, Peter Raeymakers, Rachel Wickert, Kim Becher +5 more
201610 citations Open access
Semantic Scholar
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
S. Ombelet, Diego Castanares-Zapatero, Fabian Desimpel, F. Hulstaert +2 more
2024Journal of Medical Virology9 citations Open access
Semantic Scholar
SHOULD CHRONIC HEPATITIS B BE TREATED AS EARLY AS POSSIBLE?
F. Hulstaert, C. Schwierz, F. Nevens, Nancy Thiry +4 more
2013International Journal of Technology Assessment in Health Care8 citations Open access
Semantic Scholar
HPV Vaccination for the Prevention of Cervical Cancer in Belgium
Nancy Thiry, Marie-Laurence Lambert, Irina Cleemput, M. Huybrechts +3 more
2007KCE Reports8 citations Open access
Semantic Scholar
Defining the role of pragmatic clinical trials in cancer clinical research: outcomes of a collaborative workshop hosted by the European Organisation for Research and Treatment of Cancer.
Fábio Cardoso Borges, W. V. D. van der Graaf, R. Saesen, S. Aebi +16 more
2025The Lancet Oncology7 citations Open access
Semantic Scholar
Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab
L. Verleye, D. Castanares-Zapatero, C. Devos, C. De Gendt +5 more
2023International Journal of Gynecological Cancer7 citations Open access
Semantic Scholar
Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest central
M. Neyt, Hanne Baeyens, Céline Pouppez, Pierre Slegers +3 more
2017Expert Review of Medical Devices7 citations
Semantic Scholar
Towards a guided and phased introduction of high-risk medical devices in Belgium
Hanne Baeyens, Céline Pouppez, Pierre Slegers, I. Vinck +2 more
20157 citations Open access
Semantic Scholar
Cervical Cancer Screening and Human Papillomavirus (HPV) Testing
F. Hulstaert, Marc Arbyn, M. Huybrechts, I. Vinck +2 more
2006KCE Reports7 citations Open access
Semantic Scholar
Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population‐based study in Belgium
D. Castanares-Zapatero, L. Verleye, Carl Devos, Nancy Thiry +5 more
2024International Journal of Dermatology6 citations Open access
Semantic Scholar
Belgian observational survival data (incidence years 2004-2017) and expenditure for innovative oncology drugs in twelve cancer indications.
Mattias Neyt, C. Devos, Nancy Thiry, G. Silversmit +5 more
2023European Journal of Cancer6 citations
Semantic Scholar
Evidence gaps for drugs and medical devices at market entry in Europe and potential solutions
F. Hulstaert, Céline Pouppez, Célia Primus-de Jong, K. Harkin +1 more
20216 citations Open access
Semantic Scholar
Publicly funded Practice-oriented Clinical Trials
Mattias Neyt, T. Christiaens, J. Demotes, F. Hulstaert
20156 citations Open access
Semantic Scholar
Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU.
L. Annemans, I. Cleemput, F. Hulstaert, S. Simoens
2012Journal of Comparative Effectiveness Research6 citations
Semantic Scholar
Stimulating pharmaceutical innovation in the EU
L. Annemans, I. Cleemput, F. Hulstaert, S. Simoens
2011Expert review of pharmacoeconomics & outcomes research6 citations Open access
Semantic Scholar
The increasing role of health economic evaluations in drug development
L. Annemans, I. Cleemput, S. Simoens, F. Arickx +2 more
20106 citations
Semantic Scholar
Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium
Yves Horsmans, Nancy Thiry, M. le Polain, Michael Adler +6 more
2010KCE Reports6 citations Open access
Semantic Scholar
Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology
M. Van den Bulcke, Lorena San Miguel, Roberto Salgado, Els De Quecker +8 more
2015KCE Reports5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Neyt×12
Invite
M. Neyt — researcher profile on SciRah
I. Vinck×7
Invite
I. Vinck — researcher profile on SciRah
Nancy Thiry×7
Invite
Nancy Thiry — researcher profile on SciRah
Mattias Neyt×7
Invite
Mattias Neyt — researcher profile on SciRah

×6

Invite

S. Stordeur — researcher profile on SciRah

Invite

I. Cleemput — researcher profile on SciRah

Invite

S. Simoens — researcher profile on SciRah

N. Van Damme×4

Invite

N. Van Damme — researcher profile on SciRah

H. van Brabandt×4

Invite

H. van Brabandt — researcher profile on SciRah

Céline Pouppez×4

Invite

Céline Pouppez — researcher profile on SciRah

Invite

L. Annemans — researcher profile on SciRah

Invite

J. Demotes — researcher profile on SciRah